AROVELLA THERAPEUTICS LIMITED - Corporate Spotlight

Market Cap $168.2M Add to my watchlist

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on... Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

No Corporate Spotlight currently available.

(20min delay)
Last 18.5¢		Change 0.005(2.78%)		Mkt cap ! $168.2M

Open	High	Low	Value	Volume
18.0¢	18.5¢	17.5¢	$307.9K	1.716M

Buyers (Bids)

No.	Vol.	Price($)
11	593788	17.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.5¢	267231	5

View Market Depth

No.	Vol.	Price($)
9	522019	0.145
9	691675	0.140
8	293762	0.135
6	560114	0.130
6	411775	0.125

Price($)	Vol.	No.
0.150	373508	5
0.155	579509	7
0.160	253864	5
0.165	155900	5
0.170	238869	4

Last trade - 16.10pm 03/12/2024 (20 minute delay)


Last 18.0¢		Change 0.005 ( 0.00 %)
Open	High	Low	Volume
18.0¢	18.0¢	17.5¢	894993
Last updated 15.19pm 03/12/2024 ?

ALA (ASX) Chart